Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis
1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in ...
1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in ...
1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of ...
1. 91% of patients receiving bimekizumab 320 mg every 4 weeks achieved ≥ 90% improvement from baseline in the Psoriasis ...
1. A significantly greater percentage of both roflumilast groups had clear or nearly clear skin compared to the control group ...
In this randomized controlled trial, 605 patients with moderate-to-severe chronic plaque psoriasis were assigned to receive 150 mg risankizumab subcutaneously ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.